Although these products might confer significant advantages over the currently available treatments, there is still a huge unmet need for drugs that prevent the progression of COPD. Companies are ...
Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
Tudorza and Duaklir are inhaled respiratory drugs for chronic obstructive pulmonary disease (COPD) – and at the time of the deal Tudorza (aclidinium bromide), a long-acting muscarinic agonist ...
Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing drugs, according to a new study.
Hosted on MSN4mon
GSK's Respiratory Drug Nucala Meets Goal in COPD StudyGSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback